HARMONi-6 Results: Ivonescimab’s 34% Survival Benefit Redefines First-Line Squamous NSCLC

A Statistically Clean OS Win Against an Active Control

The Phase III trial enrolled 532 patients and randomized them to ivonescimab plus platinum-doublet chemotherapy or the PD-1 inhibitor tislelizumab plus the same chemotherapy backbone. The trial was not tested against a placebo—it was tested against an established, active PD-1-based standard .

At a prespecified interim analysis, the Independent Data Monitoring Committee confirmed the trial had met its key secondary endpoint of overall survival . The top-line numbers:

• OS hazard ratio: 0.66 (95% CI: 0.50–0.87; p = 0.0017), representing a 34% reduction in the risk of death .
• 24-month OS rate: 64.7% for ivonescimab plus chemotherapy versus 48.6% for tislelizumab plus chemotherapy .
• The OS benefit was selected for the ASCO 2026 Plenary Session, a slot historically reserved for practice-changing data .

The OS result followed the progression-free survival (PFS) data released the previous October. The PFS primary endpoint was unambiguous:

• Median PFS: 11.14 months (ivonescimab arm) vs. 6.90 months (tislelizumab arm) .
• PFS hazard ratio: 0.60 (95% CI: 0.46–0.78; p < 0.0001), a 40% reduction in the risk of progression or death .

The 4.24-month absolute improvement in median PFS is substantial in a population long considered a difficult setting for immunotherapy advancement.

Uniform Benefit: From PD-L1 Negative to High Expressers

One persistent question with immune-based therapies is whether they work for everyone—or only for patients whose tumors express high levels of PD-L1. HARMONi-6’s subgroup analysis suggests ivonescimab largely closes that gap .

In patients with PD-L1 tumor proportion score (TPS) below 1%, the PFS hazard ratio was 0.55—meaning those who often derive the least benefit from PD-1 monotherapy still saw a strong treatment effect . For patients with PD-L1 TPS ≥1%, the PFS hazard ratio was 0.66, and across all tested PD-L1 strata (1–49% and ≥50%), the hazard ratios consistently favored the ivonescimab arm .

Press releases and SEC filings from both Akeso and Summit confirmed that the OS benefit, like PFS, was observed across all prespecified subgroups, including age, sex, ECOG performance status, smoking history, and PD-L1 expression . The concordance between PFS and OS across subgroups is uncommon and strengthens the biological hypothesis that simultaneously blocking PD-1 and VEGF is fundamentally different from blocking PD-1 alone.

The Global Path: Summit’s FDA Clock and the Keytruda Showdown

Summit Therapeutics controls ivonescimab’s rights outside of China and is running the global development program. The regulatory engine is now spinning fast.

First PDUFA Date: November 14, 2026

On January 29, 2026, the FDA accepted Summit’s Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed on prior tyrosine kinase inhibitor (TKI) therapy. The application is based on the multiregional Phase III HARMONi study .

The FDA set a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026 . If approved, ivonescimab would enter the U.S. market first in the post-TKI EGFR-mutant setting—a smaller but high-need population—before a subsequent squamous NSCLC filing based on HARMONi-6.

HARMONi-3: The Trial That Matters Most

Summit’s HARMONi-3 trial is the program’s centerpiece. It directly compares ivonescimab plus chemotherapy to pembrolizumab (Keytruda) plus chemotherapy as first-line treatment for metastatic NSCLC, with separate cohorts for squamous and non-squamous tumors . Keytruda-based chemoimmunotherapy is the dominant global standard; displacing it requires a head-to-head win.

Summit enrolled the squamous cohort and, as of early 2026, completed investigator screening and amended the statistical analysis plan to allow an interim PFS analysis in the second quarter of 2026 . That interim readout could open a dialogue with the FDA about a potential early filing for the squamous indication, well ahead of the final PFS and OS analysis.

The total trial is designed to enroll approximately 1,080 patients, with PFS and OS as dual primary endpoints . If HARMONi-3 delivers a statistically significant PFS and OS advantage against the Keytruda standard, ivonescimab would become the first drug to beat pembrolizumab plus chemo in a head-to-head Phase III NSCLC trial—and the commercial prize would be significant.

Why This Matters for Practice

Squamous NSCLC represents roughly 25–30% of all NSCLC cases. It has historically been excluded from anti-angiogenic trials due to an elevated risk of severe bleeding. Ivonescimab’s dual mechanism—blocking PD-1 while simultaneously starving tumors of their VEGF-driven blood supply—appears to generate efficacy well beyond the sum of its parts, without the catastrophic toxicity that once shelved VEGF inhibition in this group.

The HARMONi-6 survival data convert a promising PFS signal into an overall survival argument. In a disease where median overall survival with standard PD-1 chemoimmunotherapy has remained stubbornly under two years, a 24-month OS rate approaching 65% is clinically meaningful.

The next catalysts are tightly packed: the November 2026 PDUFA date for the post-TKI EGFR setting, a potential BLA submission for the squamous frontline indication after HARMONi-6, and the interim readout from HARMONi-3. For a molecule that entered global Phase III development only in 2023, ivonescimab’s timeline is unusually compressed—and the lung cancer community is watching closely.